BCG — old workhorse, new skills

https://doi.org/10.1016/j.coi.2017.06.007Get rights and content
Under a Creative Commons license
open access

Highlights

  • Several recombinant live vaccine candidates are in the development pipeline.

  • The most advanced vaccine candidate will reach Phase II/III trials in 2017.

  • Apoptosis and autophagy facilitate presentation of vaccine antigens.

  • Mucosal BCG vaccination is more effective than parenteral vaccination in mouse models.

  • BCG reduces infant mortality due to non-specific effects on immunity.

Bacille Calmette-Guérin (BCG), the only tuberculosis (TB) vaccine in clinical practice, has limitations in efficacy, immunogenicity and safety. Much current TB vaccine research focuses on engineering live mycobacteria to interfere with phagosome biology and host intracellular pathways including apoptosis and autophagy, with candidates such as BCG Δzmp1, BCG ΔureC::hly, BCG::ESX-1Mmar, Mtb ΔphoP ΔfadD26, Mtb ΔRD1 ΔpanCD and M. smegmatis Δesx-3::esx-3(Mtb) in the development pipeline. Correlates of protection in preclinical studies include increased central memory CD4+ T cells and recruitment of antigen-specific T cells to the lungs, with mucosal vaccination found to be superior to parenteral vaccination. Finally, recent studies suggest beneficial non-specific effects of BCG on immunity, which should be taken into account when considering these vaccines for BCG replacement.

Cited by (0)

3

These authors contributed equally to this work.